Miguel Sampayo

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

Ramón Palmero, Álvaro Taus, Santiago Viteri et al. · JCO Precision Oncology · 2021 · 62 citations

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial

Antonio Llombart‐Cussac, Xavier Pivot, Laura Biganzoli et al. · The Breast · 2014 · 47 citations · Full text

An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study

Ignacio Romero, María Jesús Rubio, Manuel Hidalgo Medina et al. · Gynecologic Oncology · 2020 · 20 citations

Medicine, Clinical Endpoint, Gynecology +8

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

Vanesa Ortega, Antonio Antón, Isabel Garau et al. · Clinical Breast Cancer · 2018 · 17 citations

Breast Oncology, Phase Ii, Single-arm Trial +9

<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

Alexander Paterson, Peter C. Lucas, Stewart Anderson et al. · JNCI Cancer Spectrum · 2021 · 17 citations · Full text